View from the Fc: Five Rules for mAb Development Risk Reduction
August 1, 2024
Authors: SeromYx Team (2024)
White Paper
Summary:
Understanding and measuring immune function remains a major challenge for immunotherapy development. This publication highlights lessons from SeromYx’s work with monoclonal antibody developers, emphasizing the value of Fc effector function profiling in reducing failure rates and improving therapeutic outcomes.
The World Vaccine Congress Europe 2025
Festival of Biologics
The Fc-Mediated Effector Function Summit
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1). Journal: mAbs
Authors: Osborn, G., López-Abente, J., Adams, R. et al.
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
Authors: P. Hsueh, M. Friedman, S. Jatiani (2024) Application Note
Authors: Atyeo et al. Immunity (2020)
